Royalty Pharma's (NASDAQ:RPRX) Solid Earnings May Rest On Weak Foundations
Royalty Pharma's (NASDAQ:RPRX) Solid Earnings May Rest On Weak Foundations
Royalty Pharma plc's (NASDAQ:RPRX ) stock didn't jump after it announced some healthy earnings. We think that investors might be worried about some concerning underlying factors.
royalty pharma股票在宣布有利润增长后并未上涨。我们认为投资者可能担心一些令人担忧的潜在因素。
How Do Unusual Items Influence Profit?
非常规项目如何影响利润?
For anyone who wants to understand Royalty Pharma's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from US$349m worth of unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And, after all, that's exactly what the accounting terminology implies. If Royalty Pharma doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
对于任何想了解royalty pharma利润超出法定数字的人,重要的是要注意,在过去十二个月里,法定利润中获得了34900万美元的飞凡项目。我们不能否认,更高的利润通常让我们感到乐观,但我们更希望利润能持续。当我们综合分析了成千上万家公开上市公司的数据后,我们发现,某一年度因飞凡项目获利的情况通常不会在下一年重复。毕竟,这正是会计术语所意味的。如果royalty pharma没有看到这项贡献的重复,那么其他条件相等,我们预计其利润在当前年度将会下降。
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
这可能会让您想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看基于其估计的未来盈利能力的互动图表。
Our Take On Royalty Pharma's Profit Performance
我们对royalty pharma的利润表现看法
We'd posit that Royalty Pharma's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that Royalty Pharma's statutory profits are better than its underlying earnings power. But the happy news is that, while acknowledging we have to look beyond the statutory numbers, those numbers are still improving, with EPS growing at a very high rate over the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. For example - Royalty Pharma has 3 warning signs we think you should be aware of.
我们认为,Royalty Pharma的法定收益并不能完全反映其持续生产力的情况,因为存在一笔较大规模的飞凡项目。因此,我们认为可能Royalty Pharma的法定利润要优于其潜在的收益能力。但令人高兴的消息是,尽管我们必须超越法定数字,这些数字仍在改善,EPS在过去一年增长速度非常快。最终,要全面了解公司,不仅仅要考虑以上因素。有这个观念很重要,要彻底了解风险才会考虑投资一只股票。例如 - 大家认为你应该知道Royalty Pharma有3个警示信号。
Today we've zoomed in on a single data point to better understand the nature of Royalty Pharma's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
今天,我们放大了一个单一数据点,以更好地了解Royalty Pharma利润的性质。但有许多其他方法可以了解一个公司。例如,许多人认为股权回报高是有利的商业经济指标,而另一些人喜欢‘跟随资金’并发现内部人士正在购买的股票。因此,您可能希望查看这些自由收集的公司,这些公司拥有高股权回报率,或者有高内部所有权的股票列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。